Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
AIMS: To assess the clinical effectiveness of pegaptanib sodium and ranibizumab for neovascular age-related macular degeneration (AMD). METHODS: A systematic review of randomised controlled trials (RCTs) identified through searching 12 electronic databases, bibliographies and consultation with experts and manufacturers. RCTs were eligible if they assessed the effects of pegaptanib or ranibizumab with best supportive care, sham injection or photodynamic therapy (PDT) on patients with subfoveal choroidal neovascularisation associated with wet AMD and examined outcomes including visual acuity and adverse events. RESULTS: Three RCTs of ranibizumab (MARINA, ANCHOR, FOCUS) and two of pegaptanib (VISION study) met the inclusion criteria. The RCTs included patients with different lesion types. The studies showed statistically significant benefit on different measures of visual acuity for patients receiving pegaptanib, ranibizumab or ranibizumab with PDT compared to control (sham injection, PDT or sham injection with PDT) after 12 months. These differences appeared to be clinically significant. Although adverse events were common among those receiving pegaptanib or ranibizumab, they were considered mild to moderate in nature. Meta-analysis of ranibizumab trials and indirect comparison of the two drugs were not possible due to differences in the study populations' lesion types. However, results from the RCTs of ranibizumab tended to show a greater effect on visual acuity than results from the RCT of pegaptanib. CONCLUSIONS: Pegaptanib and ranibizumab appear to slow or stop the progression of neovascular AMD. Uncertainty remains over the relative benefits of pegaptanib compared with ranibizumab and other unlicensed drugs (eg, Avastin), due to the nature of the evidence. Head-to-head RCTs and economic evaluations comparing these alternatives are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Systematic Reviews in Health Care: Meta‐Analysis in Context
(2001) · doi:10.1002/9780470693926 · Cited by 1,693
Heier, J. S. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.11.1532 · Cited by 304
Pegaptanib Sodium for Neovascular Age-Related Macular Degeneration
D’Amico, D. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.02.027 · Cited by 260
Cited by
Directed Evolution: Methodologies and Applications
Wang, Y., Xue, P., Cao, M., Yu, T., Lane, S. T., & Zhao, H. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00260 · Cited by 719
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Rein, D. B. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.58 · Cited by 344
The Pathogenesis of Pterygium: Current Concepts and Their Therapeutic Implications
Chui, J., Girolamo, N. D., Wakefield, D., & Coroneo, M. T. (2008) · The Ocular Surface · doi:10.1016/s1542-0124(12)70103-9 · Cited by 276
INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M. (2009) · Retina · doi:10.1097/iae.0b013e3181a94f01 · Cited by 255
Metadata
- Authors
- Takeda, A. L., Colquitt, J., Clegg, A. J., & Jones, J.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2007-05-02
- Volume
- 91
- Issue
- 9
- Pages
- 1177-1182
- ISSN
- 0007-1161 (ISSN-L)
- OpenAlex
- W2045476755
- Cited by
- 91
- References
- 6
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. https://app.cochat.ai/papers/10.1136/bjo.2007.118562
- The paper
- Takeda, A. L., Colquitt, J., Clegg, A. J., & Jones, J. (2007). Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. British Journal of Ophthalmology. https://doi.org/10.1136/bjo.2007.118562
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.